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INTRODUCTION
Prostatic tumors are the most frequently diagnosed tumors in
American males. Yet, the mechanisms underlying prostate tumor
initiation, progression and escape from regulation by androgen are
not well understood. Since many developmental events are
recapitulated during tumorigenesis, understanding prostate
development will aid comprehension of prostate tumorigenesis.
Prostate development starts at embryonic day 17 (E17), when a
group of urogenital epithelial cells in the hindgut endoderm grow
out into the surrounding mesenchyme and form the anterior,
ventral, dorsal and lateral prostate buds (Donjacour and Cunha,
1988; Sugimura et al., 1986). The prostatic buds then undergo
extensive branching morphogenesis prior to puberty. At pubertal
stages, the prostate rudiments grow rapidly; the ducts elongate from
distal points and exhibit complex infolding of the intraductal
mucosum. It has been shown that several growth factor families,
including the fibroblast growth factor (FGF) family, play important
roles in regulating prostate morphogenesis (Donjacour et al., 2003;
Huang et al., 2005; Lin et al., 2007a; Thomson and Cunha, 1999).
The FGF family consists of 22 gene products controlling a wide
spectrum of cellular processes. The FGF elicits regulatory signals
by activating FGF receptor (FGFR) transmembrane tyrosine kinases
encoded in isoforms of four genes (McKeehan et al., 1998; Powers
et al., 2000; Wang and McKeehan, 2003). In the prostate, members
of the FGF and FGFR families are partitioned between the epithelial
and mesenchymal compartments and underlie directionally specific
and reciprocal communication between the two compartments.
Ablation of the FGF signaling disrupts prostate development
(Donjacour et al., 2003; Huang et al., 2005; Lin et al., 2007a).
Aberrant FGF signaling, in particular the reduction in the resident
epithelial FGFR2IIIb, the ectopic appearance of FGFR1, and the
overexpression of FGF9 in epithelial cells, is associated with
prostate tumor progression (Giri et al., 1999; Jin et al., 2003b;
Kwabi-Addo et al., 2001; Lu et al., 1999; McKeehan et al., 1998;
Polnaszek et al., 2004; Ropiquet et al., 1999). 
Recently, we reported that ablation of FGFR2 in prostatic
epithelial precursor cells in early prostate development inhibits
prostatic ductal branching morphogenesis and the acquisition of
androgen dependency during development (Lin et al., 2007a).
Similarly, ablation of Fgf10, a ligand for the FGFR2IIIb isoform,
also disrupts prostate development (Donjacour et al., 2003; Huang
et al., 2005). The detailed mechanism underlying how FGFR2 elicits
intracellular regulatory signals in the prostate remains elusive.
FRS2 is an adaptor protein that links FGFR kinases to multiple
downstream signaling pathways. Activation of the MAP kinase and
phosphatidylinositol 3 (PI3) kinase pathways by FGFR1 is primarily
mediated via FRS2 (Kouhara et al., 1997; Lin et al., 1998; Ong et
al., 1996; Rabin et al., 1993). Whether the FRS2-mediated signals
are important for FGFR2 in control of prostate development and
adult tissue homeostasis remains to be determined.
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2FRS2 is generally expressed in fetal and adult tissues
(McDougall et al., 2001). Disruption of Frs2 alleles in early
embryogenesis is lethal (Hadari et al., 2001). To circumvent this
limitation and enable studies on later stages of development, we
employed the loxP-Cre recombination system to inactivate Frs2
alleles in the prostate epithelium by crossing mice carrying loxP-
flanked Frs2 (Frs2flox) (Lin et al., 2007b) and Nkx3.1Cre knock-
in alleles (Lin et al., 2007a). Similar to Fgfr2 ablation, disruption
of Frs2 in the prostate epithelium reduced epithelial cell
proliferation, impaired branching morphogenesis during prostate
development, and impaired post-puberty androgen-dependent
prostate regeneration. Unlike Fgfr2cn prostates, Frs2cn prostates
remained strictly dependent on androgen with respect to tissue
homeostasis. Ablation of Frs2 significantly inhibited the
initiation and progression of autochthonous mouse prostate
tumors. This indicated that FRS2-mediated mitogenic signals are
important for prostatic development and regeneration, and suggest
a role of aberrant FRS2-mediated signaling in prostate
tumorigenesis.
MATERIALS AND METHODS
Animals
Mice carrying loxP-flanked Frs2 alleles, the R26R-lacZ reporter, and the
Nkx3.1Cre knock-in alleles were bred and genotyped as described (Jin et al.,
2003b; Lin et al., 2007b; Soriano, 1999). Orchiectomy and androgen therapy
were carried out as described previously (Lin et al., 2007a). All animals were
housed in the Program for Animal Resources of the Institute of Biosciences
and Technology, and were handled in accordance with the principles and
procedures of the Guide for the Care and Use of Laboratory Animals. All
experimental procedures were approved by the Institutional Animal Care
and Use Committee.
Prostate cell and organ cultures
TRAMP-C2 cells were maintained in RD (50% RPMI, 50% DMEM)
medium with 5% FBS as described (Foster et al., 1997). For protein stability
analyses, the cells (1106 cells in 10-cm dishes) were treated with 10 g/ml
cycloheximide for the indicated times. For FGF2 response analyses, the cells
(1105 in 6-well plates) were serum starved for 24 hours prior to being
treated with 10 ng/ml FGF2 for 10 minutes.
Prostate tissues were dissected at postnatal day 0.5 as described (Lamm
et al., 2001) and transferred to 0.4 m Millicell-CM filters (Becton
Dickinson Labware Europe, Meylan, France) inside 24-well tissue culture
plates. Each well contained 0.5 ml of serum-free DMEM:Ham’s F-12 (1:1)
supplemented with 2% ITS (12.5 g/ml insulin, 12.5 g/ml transferrin, 12.5
ng/ml selenious acid), 2.5 g/ml linoleic acid-albumin (Sigma, St Louis,
MO), 25 g/ml gentamycin, 0.25 g/ml amphotericin B and 10 nM
testosterone. PI3 kinase inhibitor (LY294002) and ERK1/2 inhibitor
(Calbiochem, Darmstadt, Germany) were added to the medium at a final
concentration of 10 M where indicated. Cultures were maintained for 3
days at 37°C prior to harvest for analysis.
Histology
Prostates and prostate ducts were dissected and sectioned for histological
analyses as previously described (Lin et al., 2007a). Main ducts and distal
ductal tips were quantified from at least three animals. Data are presented as
mean±s.d. 
Hematoxylin and Eosin staining was performed on 5-m sections;
immunohistochemical analyses and in situ hybridization were performed on
7-m sections mounted on Superfrost/Plus slides (Fisher Scientific,
Pittsburgh, PA). The antigens were retrieved by autoclaving samples in 10
mM Tris-HCl buffer (pH 10.0) for 5-10 minutes or as suggested by
manufacturers of the antibodies. The source and dilutions of primary
antibodies are: mouse anti-cytokeratin 8 (1:15; Fitzgerald, Concord, MA);
mouse anti-smooth muscle -actin (1:1) and mouse anti-PCNA (1:1000)
from Sigma (St Louis, MO); mouse anti-P63 (1:150), rabbit anti-FRS2
(1/500) and rabbit anti-androgen receptor (1:150) from Santa Cruz (Santa
Cruz, CA); mouse anti-T antigens (1:500) from BD Pharmingen (Frankin
Lakes, NJ); rabbit anti-phosphoAKT (1:500) and anti-phosphoERK1/2
(1:500) from Cell Signaling Technology (Danvers, MA); rabbit anti-
probasin (1:3000) from the Greenberg laboratory (Fred Hutchinson Cancer
Research Center, Seattle, WA); and rabbit anti-PSP94 (1:2000) from the
Xuan laboratory (University of Western Ontario, London, Canada). The
TSA Plus Fluorescein System from PerkinElmer (Shelton, CT) was used to
visualize anti-FRS2, anti-phosphoAKT and anti-phosphoERK1/2
antibodies and the ExtraAvidin Peroxidase System from Sigma to visualize
all other antibodies. For whole-mount lacZ staining, the prostate tissues were
lightly fixed with 0.2% glutaraldehyde for 30 minutes. lacZ staining was
carried out by rocking in 1 mg/ml X-Gal at room temperature overnight as
described (Liu et al., 2005).
For proliferation analyses in 1- and 2-week-old prostates, the percentage
of PCNA-positive cells in the growing duct tips was determined, as most
proliferating cells were located at the most-distal part of ducts at this stage.
For 4-week-old and post-pubertal regenerating prostates, the percentage of
PCNA-positive cells in the whole gland was determined, as the proliferating
cells were randomly distributed in the whole gland. The data were collected
from at least five slides per prostate, and three prostates per genotype, and
are presented as mean±s.d.
Immunoblotting and analyses of secretory proteins
Dissected prostate tissues or TRAMP-C2 cells were homogenized in
RIPA buffer (50 mM Tris-HCl buffer pH 7.4, 1% NP40, 150 mM NaCl,
0.25% Na-deoxycholate, 1 mM EGTA, 1 mM PMSF), and extracted
soluble proteins were harvested by centrifugation. Samples containing 50
g protein were separated by SDS-PAGE and electroblotted onto nylon
membranes for western analyses with the indicated antibodies. The
dilutions of the antibodies are: anti-phosphoFRS2, 1:1000; anti-
phosphoERK1/2, 1:1000; anti-phosphoAKT, 1:1000; anti-AKT, 1:1000;
anti-FRS2, 1:1000; anti-ERK1/2, 1:3000; and anti-FGFR2, 1:1000.
For immunoprecipitation, soluble tissue lysates containing 500 g
protein were incubated with 2 g of the indicated antibodies overnight,
and then the immunocomplexes associated with 10 l protein A-
Sepharose beads were collected by centrifugation and extracted with SDS
sample buffer for western analyses. The specific bands were visualized
using the ECL-Plus chemoluminescent reagents. The films were scanned
with a densitometer and the bands quantified using Image J software
(NIH).
Secretory proteins were extracted as described (Lin et al., 2007a). The
protein concentrations were determined and adjusted to a final concentration
of 1 mg/ml with PBS. Samples containing 25 g protein were separated by
5-20% gradient SDS-PAGE and visualized by Coomassie Blue staining.
Samples of 50 g protein were used for western blotting analyses with anti-
probasin or anti-PSP94 as indicated.
Gene expression
For in situ hybridizations, paraffin-embedded tissue sections were
rehydrated, followed by 20 g/ml protease K digestion for 7 minutes at
room temperature. After prehybridization at 65°C for 2 hours, the
hybridization was carried out by overnight incubation at 65°C with 0.5
g/ml digoxigenin-labeled RNA probes for the indicated genes. Non-
specifically bound probes were removed by washing four times with
0.1DIG washing buffer at 60°C for 30 minutes. Specifically bound probes
were detected using alkaline phosphatase-conjugated anti-digoxigenin
antibody (Roche, Indianapolis, IN).
For real-time RT-PCR analyses, total RNA was extracted from prostates
using the RiboPure Kit (Ambion, Austin, TX). The first-strand cDNAs were
reverse transcribed from the RNA template using SuperScript II reverse
transcriptase (Invitrogen, Carlsbad, CA) and random primers according to
manufacturer’s protocols. Real-time PCR analyses were carried out using
the SYBR Green JumpStart Taq Ready Mix (Sigma) as instructed by the
manufacturer. Relative abundances of mRNA were calculated using the
comparative threshold (CT) cycle method and were normalized to -actin
or 18S rRNA as an internal control. The mean and s.d. among at least three
individual experiments are shown. RT-PCR products were analyzed on 2%
agarose gels for validation of products by size.
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RESULTS
Disruption of Frs2 alleles specifically in the
prostate epithelium
Previously, we reported that FGFR2 signaling is important for
prostate development and acquisition of androgen responsiveness.
To determine whether Frs2, a receptor-proximal adaptor in FGF
signaling, was essential for prostatic development, the loxP-Cre
recombination system was used to conditionally inactivate Frs2
alleles in prostatic epithelial cell precursors (Fig. 1A). Mice carrying
homozygous Frs2cn alleles were viable and fertile. Disruption of
the Frs2 in prostates was confirmed by PCR (Fig. 1B). Real-time
RT-PCR analyses revealed that expression of Frs2 in 1-week-old
Frs2cn prostates was significantly reduced compared with the
control prostates (Fig. 1C).
Frs2 expression was further characterized by in situ
hybridization with Frs2-specific probes. The results showed that
although Frs2 expression was constant in the stromal
compartment, it exhibited a spatial and temporal expression pattern
in the epithelium (Fig. 1D). In 1-week-old prostates, Frs2 was
expressed relatively uniformly at high levels in the epithelium. In 2-
week-old prostates, the expression became restricted to cells located
at distal tips of the ductal network, where the cells were actively
engaged in proliferation. In the prostates of mice at 4 weeks or older,
expression of Frs2was limited to basal epithelial and stromal cells.
No Frs2 expression was detected in luminal epithelial cells.
Ablation of Frs2 with Nkx3.1Cre diminished Frs2 expression in
the epithelial compartment of prostates, including basal and luminal
epithelial cells (Fig. 1D), whereas Frs2 expression in the stromal
cells remained intact. Thus, the basal level of Frs2 expression
indicated by RT-PCR in prostates of Frs2cn and 4-week-old control
mice was a constitutive property of stromal and basal cells.
Unlike Fgfr2cn prostates that only have dorsal and lateral lobes,
Frs2cn prostates were relatively normal and consisted of anterior,
dorsal, lateral and ventral prostate (AP, DP, LP and VP, respectively)
lobes, although these were smaller and more transparent than wild-
type prostates (see Fig. S1A in the supplementary material). The
prostates of genotype Frs2flox/flox, Frs2flox/WT, Frs2flox/cn,
Frs2WT/WT or Nkx3.1Cre, had no noticeable differences in organ
morphology and histological structures, and were all considered as
control prostates.
Ablation of Frs2 alleles in the prostate
epithelium inhibits prostatic branching
morphogenesis and growth
To improve direct visualization of branching morphogenesis, the
R26R-lacZ reporter allele was introduced into the Frs2cn mice by
crossing with mice bearing a lacZ reporter silenced by a loxP-
flanked sequence (Soriano, 1999). Activation of the R26R-lacZ
reporter by the Cre recombinase occurred concurrently with
disruption of the Frs2flox alleles in the same cells. Whole-mount
staining with X-Gal showed that similar to Fgfr2cn embryos,
prostatic buds formed at E17.5 in Frs2cn embryos with no apparent
difference to controls. Although all mutant buds formed AP, DP, LP
and VP lobes, fewer ductal branches were observed in the Frs2cn
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Fig. 1. Disruption of Frs2 alleles in
prostate epithelium. (A) Schematic
of the floxed Frs2 alleles for
conditional disruption. The genomic
DNA containing coding exons 1-5 and
adjacent introns is shown. Dashed
boxes indicate non-coding exon
sequence. The primers for PCR
genotyping are indicated by arrows.
Primers f1 and f2 amplify a 319 bp
fragment from the floxed Frs2 allele.
Primers f1 and f3 amplify a 261 bp
fragment from the Frs2-null allele;
no amplification from wild-type
alleles. (B) PCR genotyping for the
Frs2 conditional-null alleles. Genomic
DNAs extracted from each prostatic
lobe of 4-week-old mice were
analyzed by PCR using the primers
illustrated in A. (C) Total RNAs were
extracted from prostates of different
ages, and Frs2 expression was
assessed by real-time RT-PCR. The data
were normalized to -actin loading
controls and are expressed as
mean±s.d. of at least three
independent experiments. Note that
Frs2 alleles were intact in the stromal
compartment, which is likely to
account for the basal level of Frs2
expression in Frs2cn prostates.
Representative data from dorsolateral
prostate are shown. (D) In situ
hybridization of Frs2 expression in
prostates. Enlarged image of boxed area shown on the right. Note that the expression was diminished in the epithelium of Frs2cn prostates
and mature control prostates. Arrows indicate basal cells. AP, anterior prostate; DLP, dorsolateral prostate; VP, ventral prostate; M,
myristylation site; PTB, phosphotyrosine-binding site; f, Frt element; p, loxP element; F/F, homozygous Frs2flox mice; CN, Frs2cn mice. D
E
V
E
LO
P
M
E
N
T
4prostates than in controls (Fig. 2A). We then dissected each prostatic
lobe from 1-week-old mice to examine the Frs2cn prostates in more
detail. The X-Gal stain confirmed that that the complexity of the
ductal network in the Frs2cn prostates was reduced. Quantitative
analyses of ducts microdissected out of 4-week-old prostates
revealed a reduction in the number of ductal tips in every lobe of the
Frs2cn prostates (Fig. 2B). This indicated that the extent of
branching morphogenesis, but not budding, was compromised in
Frs2cn prostates.
To determine whether FRS2 protein was carried over into
mutant prostatic buds after ablation of expression by the Nkx3.1Cre-
mediated recombination, the prostate rudiments at different stages
were assessed with an anti-FRS2 antibody. FRS2 was strongly
expressed in epithelial cells of control prostate rudiments and the
expression gradually declined with development of the prostate.
Although Nkx3.1Cre is expressed prior to E17.5, FRS2 protein
remained evident in mutant epithelial cells at E18.5 and then
diminished at the neonatal stage (Fig. 3A). The number of cells
positive for P63 (also known as Trp63 – Mouse Genome
Informatics) remained relatively constant over the same period with
a slight decrease in Frs2cn prostates at later stages (Fig. 3B). Most
epithelial cells in normal prostate rudiments expressed P63 (Pu et
al., 2007). This indicated a persistence of FRS2 protein beyond
ablation of expression. Separate experiments in vitro indicated that
the half-life of FRS2 was longer than that of FGFR2 in prostate
epithelial tumor cells (Fig. 3C,D). These results indicated that the
carryover of FRS2 after ablation by recombination might be
sufficient to participate in signals that support prostatic bud
formation in early prostate morphogenesis.
Presence of the proliferating cell nuclear antigen (PCNA) showed
that the number of proliferating cells in Frs2cn distal tips was
reduced compared with controls at 1-2 weeks of age (Fig. 4A,B). At
3-4 weeks, the prostates were undergoing rapid growth associated
with puberty. The proliferating cells were widely distributed across
the prostates. Proliferation in whole dorsolateral prostate (DLP) and
AP lobes in Frs2cn prostates was also lower than in the controls
(Fig. 4A,B). Post-puberty cell proliferation at 6 weeks in both
Frs2cn and control prostates was dramatically reduced. No
difference was observed between Frs2cn and control prostates at
this stage (data not shown). Together, the results demonstrate that
FRS2-mediated signals are important for prostate cell proliferation
during development. Since these results mirror the Fgfr2 ablation,
they suggest a role of FRS2 in mediating FGFR2 mitogenic signals
in the epithelial cells during prostate development.
The expression of 22 key regulatory genes was compared
between control and Frs2cn 1-week-old prostates by real-time RT-
PCR. The Frs2cn prostates exhibited reduced expression of BMP7,
HOXb13, HOXd13 and NKX3.1 and increased expression of
FGFR4. No significant difference was observed between Frs2cn
and control prostates in the expression of the other genes tested (Fig.
4C). HOXb13, HOXd13 and NKX3.1 are highly expressed in
luminal epithelial cells and play a role in differentiation of luminal
epithelial cells (Economides and Capecchi, 2003). The results
suggest that in addition to its effects on proliferation and branching
morphogenesis, ablation of FRS2might also compromise luminal
epithelial cell differentiation.
Ablation of Frs2 reduces activation of MAP
kinase in prostatic epithelial cells
As an adaptor, FRS2 has multiple binding sites for downstream
substrate that are required for FGFR to activate the MAP kinase and
AKT pathways (Gotoh et al., 2004; Ong et al., 2000; Xu and
Goldfarb, 2001). To determine whether FRS2-mediated signals
activate the MAP kinase and AKT pathways, prostates were
harvested from mice at 1, 2 and 4 weeks of age and subjected to
immunoblot analysis of activated FRS2, ERK1/2 (also known as
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Fig. 2. Disruption of Frs2 alleles inhibits ductal branching morphogenesis in prostates. (A) The urogenital tract was dissected at the
indicated times, lightly fixed and then stained with X-Gal. Stained tissues representing each prostatic lobe are shown. Note the lack of significant
differences between Frs2cn (below) and control (above) prostate rudiments at E17.5 or later. (B) Prostatic lobes were dissected from mice at the
indicated ages. The tissues were lightly fixed and stained with X-Gal (a,b). Note that only epithelial cells in the prostate were stained. The ductal
network in each prostatic lobe from 4-week-old mice was microdissected (c-e) and the average number of tips was quantified from three prostates
and is shown as mean±s.d. (f). AP, anterior prostate; DLP, dorsolateral prostate; VP, ventral prostate; B, bladder; S, seminal vesicles; U, urethra;
F/F, homozygous Frs2flox mice; CN, Frs2cn mice; WT, wild-type Frs2.
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MAPK3/1 – Mouse Genome Informatics) and AKT (also known as
AKT1 – Mouse Genome Informatics). FRS2 was strongly
expressed and phosphorylated in 1-week-old normal prostates
relative to diminished levels in 4-week-old prostates (Fig. 5A).
Coincident with changes in FRS2, phosphorylation of ERK1/2 in
the control prostates was strong in early development and
diminished at later stages. By contrast, phosphorylation of AKT
was relatively constant. Ablation of Frs2 reduced the
phosphorylation of ERK, but not AKT (Fig. 5A,B).
Immunohistochemical analysis of tissues using anti-phosphorylated
ERK1/2 (Fig. 5C) and anti-phosphorylated AKT antibodies (Fig.
5D) confirmed the immunoblot results. In contrast to Frs2
ablation, ablation of Fgfr2 reduced both ERK1/2 and AKT
phosphorylation in addition to the expected reduction in
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Fig. 3. Depletion of FRS2 proteins in Frs2cn
prostatic rudiments. (A) Prostates were
collected at the indicated times, immunostained
with the indicated antibodies, and visualized by
confocal microscopy. The prostate epithelial cells
were identified with anti-P63 antibody. Expression
of FRS2 was assessed with anti-FRS2 antibody.
Arrows indicate prostate epithelial cells. Note that
FRS2 staining was diminished in Frs2cn
prostates at postnatal day 0.5 (P0.5). (B) The ratio
of p63-positive cells in the epithelial
compartment at different ages was calculated
from three samples. Representative mean±s.d.
values of data from triplicate samples are shown.
(C,D) Stability of FRS2 proteins as compared
with FGFR2 in prostate epithelial cells. TRAMP-C2
cells (1106) treated with cycloheximide were
lysed at the indicated times. The abundance of
FRS2 was analyzed by western blot directly from
the cell lysates (containing 50 g protein). FGFR2
in cell lysates (containing 500 g protein) was
pulled down with anti-FGFR2 antibody. The
specifically bound fractions were subjected to
western analyses (C). The specific bands were
quantitated with a densitometer and the data
presented as ratios of treated to non-treated cells
(D). CHX, cycloheximide; F/F, homozygous
Frs2flox mice; CN, Frs2cn mice.
Fig. 4. Compromised proliferation in Frs2cn
prostates during prepubertal and pubertal growth
stages. (A) Prostate tissues were collected from control
and mutant mice at the indicated ages and
proliferating cells assessed by immunostaining for
PCNA. Note that the proliferating cells mainly reside at
the distal tips of the ductal network in 1- or 2-week-old
prostates, but are randomly distributed in 4-week-old
prostates of both control and mutant mice. Arrows
indicate proliferating tips. Representative data from the
dorsolateral prostate are shown. Insets are high-
magnification views from the same sections. (B) PCNA-
stained cells in distal tips of 1- or 2-week-old prostates,
or whole prostate (4 weeks old), were scored. The ratio
of PCNA-positive to total epithelial cells was calculated
from five sections per prostate. Mean±s.d. values of
data from three prostates are shown. (C) Real-time
RT-PCR analyses of RNAs encoding the indicated genes
from 1-week-old prostates. Data were normalized to
-actin loading controls and then presented as the
relative difference to the control prostates. Mean±s.d.
values of data from three prostates are shown. AP,
anterior prostate; DLP, dorsolateral prostate; VP, ventral
prostate; F/F, homozygous Frs2flox mice; CN, Frs2cn
mice.
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6phosphorylation of FRS2 (Fig. 5A,C,D). These results suggest
that FGFR2 is a major source of FRS2 activation in prostate
epithelial cells during development, and that activation of the MAP
kinase pathway, but not the AKT pathway, by FGFR2 is likely to
be mediated by FRS2 in prostates.
ERK1/2 inhibitors in organ culture of newborn prostates were
employed to test whether inhibition of the MAP kinase pathway
mimicked the FRS2 deficiency with respect to prostatic branching
morphogenesis. Similar to tissue from Frs2cn prostates, normal
prostate tissue treated with the inhibitors exhibited decreased ductal
complexity indicative of compromised branching morphogenesis of
prostatic buds (Fig. 5E). However, inhibition of ERK1/2 did not
further decrease the ductal complexity of Frs2cn prostates,
implying that the FRS2-mediated pathway is the major activator
of the MAP kinase pathway during prostate branching
morphogenesis. PI3 kinase inhibitors also significantly reduced the
extent of ductal differentiation, similar to the effect of MAP kinase
inhibitors. This suggests that both MAP and PI3 kinase pathways are
important for prostate branching morphogenesis, but that FRS2 is
primarily an effector of FGFR2 kinases for activating the MAP
kinase pathway without compromise of the PI3 kinase pathway in
prostate epithelial cells.
Frs2 ablation compromises androgen-induced
prostatic cell proliferation without effect on
androgen-dependent secretory function
Although Frs2cn prostates were smaller overall, they exhibited a
similar epithelial infolding to normal wild-type prostates (see Fig.
S1 in the supplementary material). No significant difference was
observed in the display of luminal cell cytokeratin 8 (also known as
keratin 8 – Mouse Genome Informatics), or -actin in stromal cells,
or androgen receptor (AR) in both luminal epithelial and stromal
cells, between Frs2cn and control prostates (see Fig. S2A in the
supplementary material). Frs2cn prostates exhibited near-normal
levels of secretory proteins, although some reduction in the
production of probasin and PSP94 (also known as MSMB – Mouse
Genome Informatics) was noted in the VP lobe (see Fig. S2B,C in
the supplementary material).
Previously, we reported that ablation of the Fgfr2 alleles
interfered with the strict androgen-dependent properties of prostate
with respect to tissue homeostasis. To test whether ablation of Frs2
exhibited a similar effect, 8-week-old mice were deprived androgens
by orchiectomy. Similar to the effect on control prostates, the
androgen deprivation induced apoptosis in Frs2cn prostates within
2 days (data not shown) and the tissues atrophied in 2 weeks (see
RESEARCH ARTICLE Development 135 (4)
Fig. 5. Activation of the MAP kinase pathway is compromised in Frs2cn prostates during branching morphogenesis. (A,B) Western
analyses (A) of the indicated proteins from Triton-extracts of mouse prostates at the indicated ages. -actin was used as a loading control. Note
that phosphorylated FRS2 and ERK1/2 were prominent in 1- and 2-week-old prostates and were diminished in 4-week-old prostates, whereas
phosphorylated AKT remained constant in the prostates. The specific bands were quantitated (B) by densitometry. (C,D) Immunostaining of
phosphorylated ERK1/2 (C) and phosphorylated AKT (D) in tissue sections of 1-week-old prostates. The specific staining was visualized with
confocal microscopy. Note that phosphorylated ERK1/2 was reduced in the epithelial cells, but not in the stromal cells, of Frs2cn prostates, and
that both phosphorylated ERK1/2 and phosphorylated AKT were reduced in epithelial cells of Fgfr2cn prostates. Arrows indicate epithelial cells.
(E) Newborn prostate rudiments cultured with 10 M ERK1/2 (MEK1/2) or PI3 kinase inhibitor, as indicated, for 3 days. Arrows indicate lumens
of the prostatic ductal structures. pERK1/2, phosphorylated ERK1/2; pAKT, phosphorylated AKT; F/F, homozygous Frs2flox mice; CN, Frs2cn
mice.
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Fig. S3 in the supplementary material). This is in marked contrast to
Fgfr2cn prostates, which remained largely unresponsive to the same
androgen deprivation after 2 weeks (Lin et al., 2007a). This
suggested that resident epithelial cell FGFR2 instructed the prostate
to acquire strict dependence on androgen via pathways other than
those mediated by FRS2.
During regeneration induced by restoration of androgen,
expression of FRS2 was apparent in the restored prostate luminal
epithelial cells (Fig. 6A). Real-time RT-PCR analyses confirmed that
Frs2 expression was significantly increased in regenerating
prostates as compared with the castrated remnants (Fig. 6B). This
suggested that FRS2 plays a role in prostate regeneration. To test
this, the rate of epithelial cell proliferation was compared among
normal, FRS2 and FGFR2-deficient regenerating prostates
induced by androgen. PCNA immunostaining of proliferating cells
revealed that, similar to the effect of Fgfr2 ablation, disruption of
Frs2 significantly reduced proliferation activity in the prostate
epithelium (Fig. 6). Taken together, the results indicate that FRS2
potentially mediates mitogenic signals of FGFR2 during androgen-
induced proliferation, but FGFR2 support of androgen-dependent
gene expression in the prostate is mediated by FRS2-independent
pathways.
Ablation of Frs2 in the prostatic epithelium
inhibits prostatic tumorigenesis
Although FRS2 was not expressed in luminal epithelial cells of
mature normal prostates, it appeared prominently in luminal
epithelial cells in prostate tumors in the TRAMP mouse (Fig. 7A,B),
the tumors of which were induced by oncogenic T antigens targeted
to prostate epithelial cells (Kaplan-Lefko et al., 2003). This was
coincident with the ectopic appearance of FGFR1 in foci of high-
grade PIN and overt tumor cells in the TRAMP prostates (Fig. 7A).
These results are consistent with the previous finding that the ectopic
appearance of normally stromal resident FGFR1 is often associated
with prostate tumor progression (Jin et al., 2003a; Kwabi-Addo et
al., 2001). The significantly increased phosphorylation of FRS2,
ERK1/2 and AKT in TRAMP-C2 epithelial cell lines derived from
the TRAMP tumors induced by FGF2, indicated the presence of
active ectopic FGFR1 signaling in the tumor cells (Fig. 7C).
TRAMP-C2 cells are characterized by expression of ectopic FGFR1
(Foster et al., 1999). FGF2 is specifically recognized by ectopic
FGFR1, but not by resident FGFR2IIIb, in prostate epithelial cells
(McKeehan et al., 1998). Thus, it is likely that FRS2 plays a role
in mediation of ectopic FGFR1 in prostate tumors.
To determine whether FRS2 had any impact on tumorigenesis
in the TRAMP mice, the Frs2cn and TRAMP mice were crossed.
Histological analysis showed that by 10 weeks, the majority of
TRAMP mice carrying the floxed Frs2 alleles developed the
expected low-to-high-grade PIN lesions. PIN foci were apparent
across the whole prostate with an estimated 80% of the prostate
exhibiting various degrees and grades of PIN lesions (Fig. 7D,E).
Although the TRAMP transgenic T antigens were highly expressed
in the Frs2cn prostates, PIN lesions across the Frs2cn prostates
were fewer in number and the majority of the lesions were lower
grade than in control TRAMP mice (Fig. 7D,E). By 24 weeks, most
control TRAMP mice developed advanced, poorly differentiated
tumors, whereas tumors in the Frs2cn/TRAMP hybrids were well-
differentiated (Fig. 7D). Application of a Kaplan-Meier survival
analysis showed that ablation of Frs2 alleles significantly
increased the life span of TRAMP mice (Fig. 7F). These results
strongly suggest that ablation of FRS2-mediated signaling
pathways in prostate epithelial cells inhibits prostate tumor initiation
and progression in the TRAMP mice. and this mostly likely occurs
through the adaptor function of FRS2 with ectopic FGFR1.
DISCUSSION
Disruption of Frs2 in prostate epithelium impairs
prostatic morphogenesis
Members of the FGF family play cell-specific roles in prostatic
development, function, compartmental homeostasis and
tumorigenesis (Lin et al., 2007a; McKeehan et al., 1998). Here we
report that the expression of FRS2, a major adaptor protein in the
FGF signaling cascade, is spatiotemporally expressed and is closely
associated with prostatic cell proliferation. Although diminished in
the adult prostatic epithelium, expression of FRS2 was activated
in epithelial cells of regenerating and tumor prostates. Tissue-
specific ablation of Frs2 in prostatic epithelial precursor cells
compromised prostatic branching morphogenesis and growth.
Furthermore, ablation of Frs2 alleles retarded prostatic tumor
formation and progression in the autochthonous TRAMP mouse
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Fig. 6. Compromised proliferation activities in regenerating
Frs2cn prostates induced by androgens. (A,B) Expression of Frs2
in the epithelium of regenerating prostates. Expression of Frs2 was
assessed by in situ hybridization (A) or real-time RT-PCR (B). Data were
normalized to the abundance of 18S rRNA and are expressed as
mean±s.d. of at least three prostates. The background of Frs2
expression in the conditional mutants is from the stroma. Red arrows,
epithelial cells; black arrows, stromal cells. (C,D) Reduced androgen-
induced proliferation in Frs2cn prostates. Androgen was restored to
mice 14 days after orchiectomy to induce prostate regeneration. Tissues
were harvested at the indicated days after administration of androgen.
Proliferating cells were revealed by immunostaining with anti-PCNA
antibody (C). Red arrows, epithelial cells; black arrows, stromal cells.
(D) Representative data from the dorsolateral prostate are shown.
PCNA-positive cells were scored and reported as ratios of proliferating
cells to total cell numbers. Mean±s.d. values of data from at least three
prostates are shown. (E) The average wet tissue weights of normal
prostates before castration (Cont), 2 weeks after the operation (Cas),
and 14 days after administration of androgen (Reg). Mean±s.d. values
of data from three samples are shown. F/F, homozygous Frs2flox mice;
CN, Frs2cn mice. D
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8model of prostate cancer. The data demonstrate that FRS2 is
important for prostatic development and growth, and imply that
aberrant activation of FRS2-mediated signaling might contribute
to prostatic tumorigenesis.
FRS2 in mediation of the FGF10/FGFR2 signals for
prostate development and growth
During prostatic organogenesis, FGF7 and FGF10 are expressed in
the mesenchyme, and FGFR2IIIb, the cognate receptor for FGF7/10,
is expressed in the epithelium of the distal parts of elongating and
branching ducts in prostatic rudiments (Huang et al., 2005; Thomson
and Cunha, 1999). Ablation of FGFR2 in prostate epithelial cell
precursors inhibits cell proliferation and cellularity throughout
prostatic development (Lin et al., 2007a). Because of its role as a
general adaptor bridging activated FGFR kinases and the MAP
kinase, ablation of Frs2 potentially compromises activity of the
FGF7/10-FGFR2IIIB axis. Together with the data showing that
ablation of Fgfr2 concurrently reduced activation of FRS2 and the
MAP kinase pathway, the results suggest that FGFR2 signals for
activating the MAP kinase pathway and regulating cell proliferation
in prostate epithelial cells were mediated by FRS2. By contrast,
phosphorylated AKT was reduced in Fgfr2cn, but not in Frs2cn,
prostates (Fig. 5). This indicates that FGFR2 activates the AKT
pathway via an FRS2-independent mechanism. Unlike Fgfr2
ablation, which abrogates anterior and ventral prostatic bud
formation, ablation of FRS2 did not disrupt development of
prostatic buds. It is not uncommon that the prostate has a lobe-
specific response to morphoregulatory genes (Economides and
Capecchi, 2003; Podlasek et al., 1997; Pu et al., 2007). Because the
apparent half-life of FRS2 is longer than that of FGFR2, our results
could not resolve whether FGFR2 signals in prostatic bud formation
were mediated by FRS2-independent pathways or by the carryover
of FRS2. Further experiments are needed to clarify this issue.
Several signaling pathways, including those of SHH, Notch, BMP
and FGF, have been implicated in prostate development. Ablation
of Frs2 or Fgfr2 alleles reduced expression of HOXd13. In
addition, ablation of Frs2 reduced expression of BMP7 and
HOXb13 and increased expression of FGFR4, FGF7, FGF10 and
BMP4. Of this set of regulators, ablation of Fgfr2 reduces
expression of BMP4 (Lin et al., 2007a). This difference suggested
that FGFR2 signaling in prostate epithelial cells is at least in part
mediated by FRS2, but that FGFR2 is not the only upstream
activator of FRS2 in the prostate. Notably, HOXb13 is only
expressed in ventral prostates. Concurrent inactivation mutations of
both Hoxb13 and Hoxd13 cause severe hypoplasia in ventral
prostate morphogenesis (Economides and Capecchi, 2003). Our
results suggest that both Hoxb13 and Hoxd13 might be downstream
targets of FRS2-mediated signaling cascades in the prostate, and that
FRS2-mediated signals are crucial for ventral epithelial cell
differentiation. The expression of PSP94 and probasin, which are
secretory proteins characteristic of mature luminal epithelial cells,
was consistently and significantly reduced in Frs2cn ventral
prostate (see Fig. S2B in the supplementary material). These results
suggest that ablation of Frs2 compromises luminal epithelial cell
differentiation in ventral prostate. Further experiments will be
carried out to test this possibility.
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Fig. 7. Ablation of FRS2 in the
prostatic epithelium inhibits
tumorigenesis in the TRAMP prostatic
tumor model. (A,B) Expression of Frs2
and Fgfr1 at the mRNA level was assessed
in TRAMP prostates by in situ hybridization
(A) and RT-PCR (B). Red arrows, epithelial
cells; black arrows, stromal cells. Inset, wild-
type control showing no expression of
Fgfr1 in the epithelial compartment. T1 and
T2, different, individual TRAMP tumors; C2,
the C2 cell line derived from TRAMP
tumors; PWT, prostates of 6-month-old
wild-type mice; PTRAMP, prostates of 3-
week-old TRAMP mice in which PIN lesions
are minimal. Brain and liver were used as
positive controls; -actin as a loading
control. (C) Treatment of TRAMP-C2 cells
with FGF2 (10 ng/ml) for 10 minutes after
serum starvation for 24 hours. Cells were
lysed and the lysates analyzed by western
blot with the indicated antibodies.
(D) Prostate tissue sections were prepared
from TRAMP mice with homozygous Frs2-
null or Frs2 floxed alleles at the indicated
ages and stained with Hematoxylin and
Eosin (HE) or analyzed by
immunohistotaining with anti-T-antigen
antibody. Blue arrows, focal lesions; green
arrows, normal epithelial cells. (E) PIN foci
in prostates of 10-week-old TRAMP mice
were identified as defined (Park et al., 2002), and the percentage area occupied by lesions quantitated. Mean±s.d. values of data from five
prostates are shown. (F) Mortality of TRAMP mice with the indicated Frs2 alleles was determined from daily observation over 250 days. The
percentage of mice that survived to the indicated ages is shown. pFRS2, phosphorylated FRS2; pERK1/2, phosphorylated ERK1/2; pAKT,
phosphorylated AKT; F/F, homozygous TRAMP-Frs2flox mice; CN, TRAMP-Frs2cn mice.
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Knock-in of the Cre cDNA to the Nkx3.1 locus disrupts one
Nkx3.1 allele. Consistent with an earlier report that verified reduced
expression of Nkx3.1 in heterozygous Nkx3.1-null prostates (Bhatia-
Gaur et al., 1999), our results showed a reduction in expression of
Nkx3.1 in Frs2cn prostates. By contrast, expression of Nkx3.1 in
Fgfr2cn prostates that also carry only one Nkx3.1 allele remained
similar to that in controls (Lin et al., 2007a). Others reported that
Nkx3.1 expression in prostate is regulated both by androgen and
FGF signaling pathways (Pu et al., 2007). Thus, it is possible that
expression of Nkx3.1 is repressed by FGFR2 via FRS2-
independent pathways and that the repression is alleviated upon
ablation of FGFR2 and to a degree sufficient to result in a net
expression of Nkx3.1 equal to that of wild-type prostates. It is also
possible that loss of FGFR2 activates the non-canonical expression
of Nkx3.1.
Ablation of Frs2 alleles attenuates androgen-
induced prostatic regeneration
Ablation of Fgfr2 alleles compromises the acquisition of
dependence of the prostate on androgen with respect to tissue
homeostasis. By contrast, FRS2-deficient prostates remained
strictly androgen-dependent. Similar to controls, Frs2cn prostates
responded to androgen deprivation within 24 hours (see Fig. S3 in
the supplementary material and data not shown). This and the fact
that FRS2 was very low or absent in luminal epithelial cells of
mature prostates, suggest that FRS2 is not essential to FGFR2
signaling with regard to its effects on the androgen-dependence of
adult prostates.
The prostate is one of the few organs that have regenerative
capacity in mice. Deprivation of androgen by orchiectomy and
subsequent restoration induces rapid regression and regeneration,
respectively. Although expression of FRS2was very low or absent
in the mature resting prostate epithelium, its expression was
significantly increased in the regenerating epithelial cells induced
by androgen. Although, overall, the androgen-induced regeneration
of the prostate was not blocked by the absence of FRS2, the rate
and extent of proliferation during the process were compromised
(Fig. 6). Thus, the elevated expression of FRS2 in regenerating
epithelial cells contributes to the rate of androgen-induced prostate
regeneration, but is not essential for it.
FRS2-mediated signals in prostatic tumorigenesis
FRS2 has four tyrosine phosphorylation sites for GRB2 binding
that link the FGFR kinase to the PI3 kinase/AKT pathway, and two
for SHP2 (also known as PTPN11 – Mouse Genome Informatics)
binding that link it to the MAP kinase pathway and are important
for mediating mitogenic signals of FGFR (Gotoh et al., 2004;
Kouhara et al., 1997; Ong et al., 1996; Ong et al., 1997; Xu and
Goldfarb, 2001). The four GRB2-binding sites are required for
mediating signals to activate the FiRE enhancer element of the
mouse syndecan 1 gene (Zhang et al., 2007). We previously
reported that FRS2 phosphorylation by FGFR kinases in rat
prostate tumor cells is FGFR isotype-specific and associated with
the promotion of cell proliferation by the presence of ectopic
FGFR1 (Wang et al., 2002). Here we showed that from the early
branching morphogenesis to mature stages, the expression of
FRS2 in luminal epithelial cells of mouse prostates was
proportional to the number of cells actively engaged in
proliferation. Expression of FRS2was transiently activated in the
luminal epithelial cells during regeneration and appeared in PIN
lesions and tumors where the cells were also actively proliferating.
Our unpublished results using in situ hybridization have confirmed
that that Fgfr1 is not expressed in prostate epithelial cells during
development, or during androgen-induced regeneration, or in
resting mature prostates. Moreover, prostate epithelial cell-specific
ablation of Fgfr1 using Nkx3.1Cre induced no detectable
abnormalities in prostate development or regeneration of mature
prostates. However, FGRF1 was apparently expressed in the
epithelial cells of lesion foci in the TRAMP prostate (Fig. 7A).
Thus, the coincidence of the ectopic appearance of FGFR1 coupled
with the constitutive expression of FRS2might support and drive
the neoplastic properties of the tumors, particularly with respect to
mitogenesis. Prevention of expression of ectopic FGFR1 in tumor
epithelial cells by a cross between ablation of the Fgfr1 alleles
specifically in prostate epithelial cells and the TRAMP mice should
shed light on this subject. Together, the results reveal that the
ectopic FGFR1/FRS2 signaling axis is a feature of the TRAMP
tumor epithelial cells. Disruption of the axis by ablation of the
Frs2 alleles is likely to interfere with tumor initiation and
progression in the TRAMP model.
In summary, we report that FRS2 is spatiotemporally expressed
in the prostatic epithelium and plays a role in prostate development,
androgen-driven regeneration and tumorigenesis. The major role
appears to be in mediation of prostatic epithelial cell proliferation in
these three processes, rather than a direct effect on androgen
responsiveness and differentiated function. The prostate epithelial
cell-specific Frs2cn mice provide an additional useful model for
scrutinizing not only the molecular mechanisms underlying prostate
growth and development, but also how prostate cancer cells escape
from strict controls on tissue homeostasis to propagate
autonomously.
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